PROK
ProKidney Corp.·Healthcare
1.95
2.632%(+0.05)
Market ClosedLast Updated: — ET
52W L: $0.5452W H: $7.13
PROK NEWS
defenseworld.net
Mar 27
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership. Insider and Institutional Ownership 57.3% of Phio Pharmaceuticals
globenewswire.com
Mar 25
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer.
defenseworld.net
Mar 22
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one
defenseworld.net
Mar 9
ProKidney (PROK) Projected to Post Earnings on Monday
ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.0010 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning report
seekingalpha.com
Jan 31
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.
seekingalpha.com
Jan 14
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
